BRPI0607475B8 - promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática - Google Patents

promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática

Info

Publication number
BRPI0607475B8
BRPI0607475B8 BRPI0607475A BRPI0607475A BRPI0607475B8 BR PI0607475 B8 BRPI0607475 B8 BR PI0607475B8 BR PI0607475 A BRPI0607475 A BR PI0607475A BR PI0607475 A BRPI0607475 A BR PI0607475A BR PI0607475 B8 BRPI0607475 B8 BR PI0607475B8
Authority
BR
Brazil
Prior art keywords
pancreatic
promoter
cell
insulin production
beta
Prior art date
Application number
BRPI0607475A
Other languages
English (en)
Inventor
Takashi Akamizu
Taiga Irako
Kenji Kangawa
Shuichi Koda
Naomi Wakabayashi
Original Assignee
Asubio Pharma Co Ltd
Daiichi Sankyo Co Ltd
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36927405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607475(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asubio Pharma Co Ltd, Daiichi Sankyo Co Ltd, Univ Kyoto filed Critical Asubio Pharma Co Ltd
Publication of BRPI0607475A2 publication Critical patent/BRPI0607475A2/pt
Publication of BRPI0607475B1 publication Critical patent/BRPI0607475B1/pt
Publication of BRPI0607475B8 publication Critical patent/BRPI0607475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

promotor de regeneração de célula (beta) pancreática, e promotor de produção de insulina em célula (beta) pancreática. a presente invenção refere-se a um fármaco para promover neogênese ou regeneração de células (beta) pancreáticas que produzem e secretam insulina e para promover a produção de insulina em células (beta), compreendendo grelina ou um derivado desta como um componente efetivo.
BRPI0607475A 2005-02-23 2006-02-23 promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática BRPI0607475B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005046562 2005-02-23
JP2005-046562 2005-02-23
JP2006003219 2006-01-11
JP2006-003219 2006-01-11
PCT/JP2006/303243 WO2006090767A1 (ja) 2005-02-23 2006-02-23 膵臓β細胞の再生促進剤及び膵臓β細胞におけるインスリン産生促進剤

Publications (3)

Publication Number Publication Date
BRPI0607475A2 BRPI0607475A2 (pt) 2009-09-08
BRPI0607475B1 BRPI0607475B1 (pt) 2020-02-11
BRPI0607475B8 true BRPI0607475B8 (pt) 2021-05-25

Family

ID=36927405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607475A BRPI0607475B8 (pt) 2005-02-23 2006-02-23 promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática

Country Status (11)

Country Link
US (1) US7803768B2 (pt)
EP (1) EP1862173B1 (pt)
JP (1) JP4843827B2 (pt)
KR (1) KR101295104B1 (pt)
CN (1) CN101128213B (pt)
AU (1) AU2006216218B2 (pt)
BR (1) BRPI0607475B8 (pt)
CA (1) CA2598864C (pt)
IL (1) IL184931A (pt)
RU (1) RU2403058C2 (pt)
WO (1) WO2006090767A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216722A1 (en) * 2007-09-11 2010-08-26 Dorian Bevec Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100506844C (zh) 1999-07-23 2009-07-01 寒川贤治 新的肽
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
WO2002060472A1 (en) 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedies for hyponutrition status
EP1455814B1 (en) * 2001-12-18 2012-04-04 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin for use in the treatment of insulin resistance
EP1541171B1 (en) * 2002-07-05 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Therapeutics for lowering the blood glucose level
CA2543507C (en) * 2003-10-24 2012-05-01 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
EP1749208A2 (en) * 2004-05-14 2007-02-07 Novo Nordisk A/S Functional ghs-r antagonists

Also Published As

Publication number Publication date
BRPI0607475A2 (pt) 2009-09-08
IL184931A (en) 2011-08-31
BRPI0607475B1 (pt) 2020-02-11
EP1862173B1 (en) 2014-12-17
CN101128213A (zh) 2008-02-20
JPWO2006090767A1 (ja) 2008-07-24
RU2403058C2 (ru) 2010-11-10
US20090143284A1 (en) 2009-06-04
US7803768B2 (en) 2010-09-28
JP4843827B2 (ja) 2011-12-21
AU2006216218B2 (en) 2011-08-11
RU2007135225A (ru) 2009-03-27
CA2598864A1 (en) 2006-08-31
AU2006216218A1 (en) 2006-08-31
CN101128213B (zh) 2013-05-08
KR20070110856A (ko) 2007-11-20
KR101295104B1 (ko) 2013-08-09
EP1862173A1 (en) 2007-12-05
WO2006090767A1 (ja) 2006-08-31
CA2598864C (en) 2016-02-16
IL184931A0 (en) 2007-12-03
EP1862173A4 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
BRPI0815308A2 (pt) peptídeo das pró-ilhotas de lagerhans, composição farmacûtica, método para estimular na neogêneses das ilhotas ou estimular a regeneração das ilhotas de langerhans e método para tratar uma patologia associada com a função pancreática defeituosa em um indivíduo
UA107812C2 (en) Oktahidropirolo disubstituted [3,4-c] pyrrole receptors as orexin modulators
MX346428B (es) Metodo para tratar eccema.
CL2009000782A1 (es) Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
BR112012011403A2 (pt) composição farmacêutica compreendendo um agonista glp-1 e metionina
BRPI0920914A8 (pt) Perácidos alfa-ceto e métodos para produzir e usar os mesmos.
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
BR112013010551A2 (pt) variantes de isopreno sintase para a produção aprimorada de isopreno
GT201200153A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
BRPI0715176A8 (pt) compostos de heteroarila utéis como inibidores de enzimas de ativação e1
NI200900190A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. pc33495a
MX368000B (es) Composición de colágeno y ácido hialurónico para la reparación de ligamento o tendón.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
BR112012011128A2 (pt) composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
BRPI0914684C1 (pt) uso de hsp70 ou um fragmento funcional ou variante do mesmo, e, hsp70 ou um fragmento funcional ou variante do mesmo
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0612424A2 (pt) composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
CU20120034A7 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
GT200600046A (es) Terapia de combinacion
MY168762A (en) Certain chemical entities, compositions and methods
BR112015031719A2 (pt) método para preparar aditivo de ração
CL2011003079A1 (es) Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes.
BRPI0618496A2 (pt) artigos adesivos e kit de adesivo para dentaduras, bem como método para proporcionar ajuste otomizado das mesmas
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: KYOTO UNIVERSITY (JP) , DAIICHI SANKYO COMPANY, LI

Free format text: TRANSFERIDO POR INCORPORACAO DE: ASUBIO PHAMA CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP)